Abgenix Inc
Article Abstract:
The effectivity of Abgenix Inc.'s monoclonal antibody is being tested and the company has a lot riding on this product which seeks to inhibiting blood vessel growth around certain cancerous tumors. Stock is best held in a well-diversified portfolio.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Healthcare information services
Article Abstract:
The healthcare information services industry declined an average of 5.5% overall because of less money being invested on information systems. Stocks are to be considered by investors willing to consider uncertainties in the industry.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Cerner Corp
Article Abstract:
Cerner Corp.'s earnings growth in clinical information systems should contiue in 2003 and 2004 but are likely to remain ill-supported by cash flow. Investors are advised not to enter into new commitments for now.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: